Close button
Enquiry IconContact Us

Opioids Crisis – Public Health Emergency

Opioids are the class of drugs that include illicit drugs such as heroin, codeine, fentanyl, meperidine, methadone, morphine, hydrocodone, diphenoxylate, hydromorphone, methylphenidate, oxycodone, and oxymorphone. Opioids are prescribed for pain management and treatment of cough and diarrhea. According to the survey conducted by Center for Behavioral Health Statistics and Quality (CBHSQ), in 2015, out of 20.5 million around 2 million (10%) Americans of 12 years age or older, which had a substance use disorder were on pain relievers and around 591,000 were on heroin.

Crisis in the U.S. Opioids Market

According to the New York Times analysis of state data, in 2016, drug overuse led to death of 59,000 to 65,000 people in the U.S. Around two-third of these deaths were due to opioids overuse and the number is expected to increase. According to a survey of National Institute of Drug Abuse (NIDA), deaths due to the overdose prescription of opioid pain relievers have more than tripled in the past 20 years, escalating to 16,651 deaths in the U.S. in 2010. It can be concluded from the analysis of the data (data from the survey and New York Times data), that death due to opioids have more than doubled in the past six years.

In October 2016, the U.S. government declared opioids crisis as an emergency to increase awareness among the public about overuse of opioids. The crisis also restricts doctors and pharmacy stores from over-prescribing or overstocking opioids. Furthermore, the government has approached leading pharmacy chains, insurance companies, and others for cooperation against opioid crisis. For instance, Attorney General of over 35 states sent a letter to the America’s Health Insurance Plans, national association whose members provide coverage for health care and related services, urging its members to reconsider coverage policies that may be fueling the opioid crisis in October 2017. Such measures can ensure proper usage of opioids and favor the market players in the U.S.

The U.S. opioids market was valued at US$ 12,046.3 million in 2015 and is expected to witness a moderate CAGR of 5.2% during the forecast period (2016–2024).

Figure 1. U.S. Opioids Market Size and Forecast, By Drugs (US$ Million), 2014–2024 

opoids market


Increasing incidences of chronic pain is expected to drive growth of the U.S. opioids market

According to the American Academy of Pain Medicine (AAPM), 2011, around 1.8 billion people suffered from chronic pain. Moreover, according to the National Institute of Health (NIH) estimates in 2015, one in 10 people in the U.S. suffered from chronic pain. Increasing prevalence of chronic pain is expected to result in high prescription of opioids pain relievers, which in turn is expected to fuel the market growth. Easy availability and favorable insurance policy are other major drivers for growth of the U.S. opioids market.

The analysis of Medicare prescription drug plans, which covers 35.7 million people in the second quarter of 2017, by ProPublica — an investigative journal and The New York Times — a leading U.S. newspaper, revealed that only one-third of the covered people had any access to other types of pain killer and less-risky opioids. This was attributed to low cost of opioids drugs. The scenario might change, however, due to strict monitoring from government and regulatory bodies. 

Cannabis as potential alternative for pain relief can be a threat to the U.S. opioids market

Cannabis could be the alternative therapy for opioids. Currently, medical marijuana is legal in 28 states and the District of Columbia even though it is illegal under federal law. According to a research published in Annals of Internal Medicine, in majority of cases, between 45% and 85%, medical marijuana is used for pain management. However, there is some ambiguity about medical marijuana effectiveness in pain management. Cannabis could be used as effective therapy after establishment of clinical trials. 

Some major players operating in the U.S. opioids market include Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals plc, Allergan, plc, and Pfizer Inc.

Opioids can be defined as a class of drugs, which include the drug heroin, synthetic opioids such as fentanyl, and various pain relievers prescribed legally, such as oxycodone, hydrocodone, and others. This class of drug is primarily taken for pain relief. It has been used for other medical purposes including cough and diarrhea treatment. They bind to opioids receptor and produce a desirable result. Opioids are generally safe when taken for a short time, regular use of the drug can lead to dependence and in extreme cases may even result in death.

Market Dynamics

According to the National Institutes of Health (NIH) estimates, in 2015 by the American Pain Society, nearly 50 million people in the U.S. suffered from chronic pain. Use of opioids in cancer, orthopedic, neuropathic, post-operative pain, and lower back pain is very effective. With growing incidence of chronic pain demand for opioids is also expected to increase consequently. Moreover, opioid overdose or abuse has fueled the growth of the U.S. opioids market. CVS Health’s, leading pharmacy chain, reports that company had been often asked to fill the prescription of 30 to 60 of the powerful pills at a time for conditions that required a much more limited amount.

However, in near future, the overuse or abuse is expected to come down significantly with deceleration of opioids a public health emergency in October 2017 by U.S government. The pharmacy chain, insurance companies, doctors, and all professionals related (directly or indirectly) to this crisis are being monitored closely and had been asked to co-operate to end this epidemic. This strict government intervention are restraining the growth of the U.S. opioids market.

Key features of the study:

  • This report provides in-depth analysis of the U.S. opioids market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the U.S. opioids market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals plc, Allergan, Plc., and Pfizer Inc.
  • Insights from this report will allow marketers and the management authorities of companies to make informed decision with respect to their future product launch, market expansion, and marketing tactics
  • The U.S. opioids market report caters to various stakeholders in this industry, including investors, opioid manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the U.S. opioids market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • U.S. Opioids Market, By Drugs
    • Codeine
    • Fentanyl
    • Meperidine
    • Methadone
    • Morphine
    • Hydrocodone
  • U.S. Opioids Market, By Therapeutic Application:
    • Pain Management
      • Neuropathic Pain
      • Migraine
      • Back Pain
      • Osteoarthritis Pain
      • Cancer Pain
      • Others
    • Cough Treatment
    • Diarrhea Treatment
  • Company Profiles
    • Purdue Pharma L.P.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Titan Pharmaceuticals, Inc.
    • Boehringer Ingelheim GmbH
    • Janssen Pharmaceuticals, Inc.
    • Sanofi S.A.
    • Sun Pharmaceuticals Industries Limited
    • Mallinckrodt Pharmaceuticals
    • Egalet Corporation
    • Endo Pharmaceuticals plc
    • Allergan, Plc
    • Pfizer Inc.

“*” marked represents similar segmentation in other categories in the respective section.


Frequently Asked Questions

The global opioids market is estimated to surpass US$ 51,005.8 Million by 2027.

Major players operating in the global opioids market include Pfizer, Inc., Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Actavis Plc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., and Zyla Life Sciences.

Usage of opioids may lead to adverse effects such as sedation, nausea, vomiting, constipation, urinary retention, and falls and this is one of the major factors that is expected to hamper growth of the market over the forecast period.

Increasing prevalence of lung infection, cancer, and HIV is one of the major factors that is expected to propel growth of the market over the forecast period.

Among application, analgesia segment held dominant position in the global opioids market in 2018, accounting for 67.3% share, in terms of volume.

Among regions, North America held dominant position in the global opioids market in 2018, accounting for 64.8% share in terms of volume, followed by Europe.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.